Drugs / Harvoni
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Harvoni | — | 2014-11-17 | europa.eu ↗ |
| Approved | US (FDA) | HARVONI | — | 2014-10-10 | fda.gov ↗ |
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02825212 | Feb 2016 → Jul 2019 | chronic hepatitis C virus infection, cryoglobulinemia | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT02759861 | Aug 2016 → Aug 2020 | chronic hepatitis C virus infection | University of Nebraska | Completed | No outcome recorded |
| Phase 4 | NCT02533934 | Aug 2016 → Dec 2019 | HIV infectious disease, cirrhosis of liver, hepatitis C virus infection | University of California, San Francisco | Completed | No outcome recorded |
Press releases naming this drug 14 releases
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Harvoni | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02533934 ↗ |